{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:21:26Z","timestamp":1792178486390,"version":"4.4.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.bbmt.2017.10.004","type":"journal-article","created":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T09:46:39Z","timestamp":1507887999000},"page":"13-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Virus-Specific T Cells: Broadening Applicability"],"prefix":"10.1016","volume":"24","author":[{"given":"A. John","family":"Barrett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Prockop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Bollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2017.10.004_bib0010","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1126\/science.1352912","article-title":"Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones","volume":"257","author":"Riddell","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0015","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1182\/blood-2016-01-628982","article-title":"T cells for viral infections after allogeneic hematopoietic stem cell transplant","volume":"127","author":"Bollard","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0020","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial","volume":"110","author":"Haque","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0025","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/bmt.2016.17","article-title":"Virus-specific T-cell banks for \u2018off the shelf\u2019 adoptive therapy of refractory infections","volume":"51","author":"O'Reilly","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0030","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2017.73.0655","article-title":"Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation","volume":"35","author":"Tzannou","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0035","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0040","article-title":"Adoptive immunotherapy for diseases associated with human polyomaviruses BK, JC and Merkel cell carcinoma virus","volume":"19","author":"Muranski","year":"2017","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0045","doi-asserted-by":"crossref","first-page":"242ra83","DOI":"10.1126\/scitranslmed.3008825","article-title":"Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT","volume":"6","author":"Papadopoulou","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0050","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/TP.0b013e31823328c0","article-title":"BK virus-specific T cells for use in cellular therapy show specificity to multiple antigens and polyfunctional cytokine responses","volume":"92","author":"Blyth","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0055","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.jcyt.2014.04.003","article-title":"Cellular immunotherapy for patients with reactivation of JC and BK polyomaviruses after transplantation","volume":"16","author":"Mani","year":"2014","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0060","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJM198607243150405","article-title":"Association of BK viruria with hemorrhagic cystitis in recipients of bone-marrow transplants","volume":"315","author":"Arthur","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0065","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.504.504","article-title":"Efficacy of third party BK virus (BKV) specific cytotoxic T-lymphocytes generated by ex vivo expansion for the treatment of BKV infection in stem cell transplant recipients, a phase 2 trial","volume":"128","author":"Olson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0070","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/1756285615602832","article-title":"Progressive multifocal leukoencephalopathy: current treatment options and future perspectives","volume":"8","author":"Pavlovic","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0075","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0080","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/bmt.2010.221","article-title":"Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient","volume":"46","author":"Balduzzi","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0085","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial","volume":"17","author":"Kaufman","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0090","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","article-title":"PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma","volume":"374","author":"Nghiem","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0095","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1158\/2326-6066.CIR-13-0087","article-title":"Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I","volume":"2","author":"Chapuis","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0100","author":"Centers for Disease Control and Prevention"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0105","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1172\/JCI44539","article-title":"CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21","volume":"121","author":"Chen","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0110","doi-asserted-by":"crossref","first-page":"6959","DOI":"10.1128\/JVI.00531-12","article-title":"Elite controllers with low to absent effector CD8+ T cell responses maintain highly functional, broadly directed central memory responses","volume":"86","author":"Ndhlovu","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0115","doi-asserted-by":"crossref","first-page":"10735","DOI":"10.1128\/JVI.01527-15","article-title":"The breadth of expandable memory CD8+ T cells inversely correlates with residual viral loads in HIV elite controllers","volume":"89","author":"Ndhlovu","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0120","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMoa0802905","article-title":"Long-term control of HIV by CCR5 Delta32\/Delta32 stem-cell transplantation","volume":"360","author":"H\u00fctter","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0125","doi-asserted-by":"crossref","first-page":"5391","DOI":"10.1182\/blood-2010-11-320226","article-title":"HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo","volume":"117","author":"Chapuis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0130","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nm0495-330","article-title":"Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression","volume":"1","author":"Koenig","year":"1995","journal-title":"Nat Med"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0135","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/blood.V90.6.2196","article-title":"Safety of autologous, ex vivo-expanded human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte infusion in HIV-infected patients","volume":"90","author":"Lieberman","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0140","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/4716","article-title":"In vivo migration and function of transferred HIV-1-specific cytotoxic T cells","volume":"5","author":"Brodie","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0145","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1182\/blood.V93.5.1506.405a38_1506_1510","article-title":"Rapid death of adoptively transferred T cells in acquired immunodeficiency syndrome","volume":"93","author":"Tan","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0150","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/mt.2014.207","article-title":"Broadly-specific cytotoxic T cells targeting multiple HIV antigens are expanded from HIV+ patients: implications for immunotherapy","volume":"23","author":"Lam","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0155","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.bbmt.2015.12.007","article-title":"Functionally active HIV-specific T cells that target gag and nef can be expanded from virus-na\u00efve donors and target a range of viral epitopes: implications for a cure strategy after allogeneic hematopoietic stem cell transplantation","volume":"22","author":"Patel","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0160","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody-modified T cells: CARs take the front seat for hematologic malignancies","volume":"123","author":"Maus","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0165","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/PPO.0000000000000031","article-title":"CD19-CAR trials","volume":"20","author":"Ramos","year":"2014","journal-title":"Cancer J"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0170","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.4161\/onci.22524","article-title":"How do CARs work?: early insights from recent clinical studies targeting CD19","volume":"1","author":"Davila","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0175","doi-asserted-by":"crossref","first-page":"33961","DOI":"10.18632\/oncotarget.5582","article-title":"Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0180","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/sj.gt.3302413","article-title":"T-cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120","volume":"12","author":"Masiero","year":"2005","journal-title":"Gene Ther"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0185","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood.V96.3.785.015k10_785_793","article-title":"Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects","volume":"96","author":"Mitsuyasu","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0190","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1006\/mthe.2002.0611","article-title":"A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy","volume":"5","author":"Deeks","year":"2002","journal-title":"Mol Ther"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0195","doi-asserted-by":"crossref","first-page":"132ra53","DOI":"10.1126\/scitranslmed.3003761","article-title":"Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells","volume":"4","author":"Scholler","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0200","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJMoa1300662","article-title":"Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV","volume":"370","author":"Tebas","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0205","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/mt.sj.6300124","article-title":"Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus","volume":"15","author":"van Lunzen","year":"2007","journal-title":"Mol Ther"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0210","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/nbt.1948","article-title":"An unbiased genome-wide analysis of zinc-finger nuclease specificity","volume":"29","author":"Gabriel","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0215","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nmeth.1670","article-title":"Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selection","volume":"8","author":"Pattanayak","year":"2011","journal-title":"Nat Methods"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0220","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/487439a","article-title":"HIV: shock and kill","volume":"487","author":"Deeks","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0225","first-page":"190","article-title":"A multi-step pace towards a cure for HIV: kick, kill, and contain","volume":"15","author":"Lopez","year":"2013","journal-title":"AIDS Rev"},{"key":"10.1016\/j.bbmt.2017.10.004_bib0230","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/pauz.201090026","article-title":"[HIV-1 eradication with the \"shock and kill\" strategy]","volume":"39","author":"Schiedel","year":"2010","journal-title":"Pharm Unserer Zeit"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117307590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117307590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:00:34Z","timestamp":1761058834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879117307590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S1083879117307590"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.10.004","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Virus-Specific T Cells: Broadening Applicability","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}